Immunotherapy & Tumor Biology
By dissecting tumor microenvironments and immune‑cancer cell interactions, this group identifies checkpoints and antigens critical for anti‑tumor immunity. They develop and test novel payloads—such as engineered T cells, bispecific antibodies, and oncolytic viruses—to boost selective cancer cell killing.
Their translational pipeline moves promising candidates from bench to early‑phase trials, with the goal of improving efficacy and reducing off‑target effects in solid and hematologic malignancies.
CRISPR‑Enhanced T Cell Therapies
Utilizing CRISPR/Cas9, we edit T cells to boost tumor‑homing receptors and resist inhibitory signals within the tumor microenvironment. Preclinical safety and persistence studies will inform protocol optimization. This translational pipeline aims to advance lead candidates into first‑in‑human trials.
Enzyme‑Driven Plastic Waste Bioremediation
Combining directed evolution and computational modeling, we develop enzymes capable of rapidly breaking down PET and related plastics. Studies will assess catalytic efficiency, thermal stability, and integration into safe microbial chassis. Pilot‑scale demonstrations aim to validate environmental impact and biorecycling potential.
Frequently asked questions
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.